Drug prices and trends for GS MICONAZOLE

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
GS MICONAZOLE 3 COMBO PACK	00113-0081-00	7.77321	EACH	2026-07-22
GS MICONAZOLE 7 CREAM	00113-0214-29	0.12302	GM	2026-07-22
GS MICONAZOLE 7 CREAM	00113-0825-29	0.12302	GM	2026-07-22
GS MICONAZOLE 3 COMBO PACK	00113-0081-00	7.93271	EACH	2026-06-17
GS MICONAZOLE 7 CREAM	00113-0214-29	0.12399	GM	2026-06-17
GS MICONAZOLE 7 CREAM	00113-0825-29	0.12399	GM	2026-06-17
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: July 26, 2026

GS Miconazole (Miconazole) Market Analysis and Price Projections: US and Select Global Markets

Executive summary: GS MICONAZOLE is a miconazole antifungal brand distributed by G.S. (GS) Laboratories. Public, regulator-linked pricing and IPA/IMS-style sales disclosures for the brand name are limited. Price projections therefore hinge on (1) whether GS miconazole is positioned as OTC versus Rx, (2) strength and dosage form (cream, powder, spray, gel, pessary, etc.), and (3) the market structure for generic miconazole in the specific geography. Where unit-price visibility exists for underlying generic miconazole, miconazole is typically a low-priced, highly genericized category with periodic list-price erosion. A reasonable projection framework is: steady to modest wholesale price decline in mature markets, faster erosion where multiple generic suppliers and pharmacy network substitution are active, and price stabilization only when GS maintains differentiation via package format, strength, or supply continuity rather than patent protection.

What is GS Miconazole and what products does “GS” cover?

Answer: “GS MICONAZOLE” refers to miconazole antifungal products marketed under G.S. (GS) branding. Miconazole products typically include topical formulations (creams, powders, sprays, gels) and, in some markets, vaginal preparations (pessaries/creams). The market and price outcome depend on which specific dosage form and strength the brand covers.

Which miconazole dosage forms drive the brand economics

Topical creams/ointments (most common in OTC and pharmacy channels): pricing is closely tied to generic competition and pack size.
Powders/sprays (athlete’s foot, intertrigo): often priced higher per gram than creams in order to sustain aerosol/spray manufacturing and convenience premium.
Vaginal miconazole (Rx or OTC depending on jurisdiction): tends to have higher per-unit pricing than topical creams but still faces generic pressure.

How naming ambiguity affects market sizing

Brand-name mapping for “GS MICONAZOLE” varies by country. In some markets, the GS label is used for multiple strengths and formats under the same brand umbrella. Price projections must track per-strength and per-form, not just the active ingredient name.

What is the global market for topical antifungals like miconazole, and where does GS fit?

Answer: Miconazole competes inside the broad topical antifungal market dominated by azoles (clotrimazole, miconazole, ketoconazole), allylamines (terbinafine) in some indications, and combination products. The share and pricing power for any single brand are typically low in mature geographies because generics capture most prescriptions and OTC shelf turnover.

Market drivers

High substitution rates: miconazole is off-patent in most major markets, so supply competition drives pricing.
Retail pharmacy stocking behavior: wholesalers and pharmacies favor multiple-source products to manage rebates and stock-outs.
Health-system formulary dynamics: where Rx, interchangeability and therapeutic substitution pressure brand pricing.

Market constraints

Indication limits: miconazole is strongly used for superficial dermatophyte and yeast infections but is not a first-line systemic antifungal.
Counter-positioning versus terbinafine: for tinea pedis, terbinafine can be preferred in some formularies due to shorter regimens.

How competitive is miconazole pricing versus other OTC azole antifungals?

Answer: Pricing competition for miconazole usually tracks clotrimazole and other topical azoles. The category behaves like a “commodity OTC dermatology” segment with periodic promotional pricing and recurring list-price erosion.

Typical competitive pricing structure (category behavior)

Miconazole competes on pack size and delivery system
- cream tubes vs larger jar formats
- powder vs spray convenience premium
Net price is shaped by
- pharmacy network discounts
- wholesaler margins
- promotional cycles in OTC

What this means for GS MICONAZOLE

If GS MICONAZOLE is sold with multiple generic substitutes at the shelf, GS pricing will likely converge toward the category’s low end unless it holds a niche via:

unique pack configuration
stronger dosing convenience
supply reliability that reduces stock-out losses

How do patent and exclusivity status affect GS MICONAZOLE pricing?

Answer: Miconazole is an established active ingredient. In mainstream markets, miconazole products are generally not protected by active composition-of-matter exclusivity, which limits the ability to sustain premium pricing through patent control. Price in mature geographies therefore reflects market competition rather than exclusivity.

Pricing implications

No durable monopoly pricing: absent active, enforceable formulation or method-of-use patents, GS MICONAZOLE will face generic and authorized-duplicate competition.
Formulation micro-differentiation matters: if GS holds any packaging or formulation IP that prevents direct substitution, it can slow erosion, but this is uncommon for classic topical azoles.

What is the Orange Book status of miconazole brands in the US?

Answer: Classic miconazole antifungals are widely available as generics/authorized products in the US market. For “GS MICONAZOLE” specifically, Orange Book listings are not reliably discoverable at brand level from public sources without a precise NDC-to-label mapping.

Implication for market access and price

US pricing for miconazole is mostly generic-driven: without brand-level exclusivity, US net prices are set by generic competition and rebate structures rather than regulatory exclusivity.

(This section is constrained to category-level behavior, since no brand-specific Orange Book/NDC linkage for “GS MICONAZOLE” is provided here.)

When do miconazole products lose exclusivity and how does that affect price erosion?

Answer: Miconazole’s core exclusivity period has long ended for most topical and vaginal uses in major jurisdictions. Post-exclusivity, pricing follows a standard erosion curve:

first generic entry reduces list prices
additional entrants compress further
periodic promotions drive volatility around net price

Erosion pattern to model

Year 0 to 2 after generic entry: fastest decline in net price due to substitution and wholesaler competition
Year 2 to 5: slower decline as the market reaches a stable low band
Year 5+: mostly promo-driven fluctuations unless supply disruptions occur

How to translate this to GS MICONAZOLE projections

If GS is a mature entrant in a given geography, projections should start from current observed price bands in that geography and apply category-standard decay rates (see modeling section below).

What generic entry risks exist for GS MICONAZOLE?

Answer: The main risk is additional authorized generics and standard ANDA-style competition (US) or equivalent local generic market entry (EU, MENA, LatAm). For topical azoles, the supply chain is multi-source and barriers to entry are low once formulation know-how and quality systems are established.

Key generic entry vectors

Authorized generics under same label strengths
Multiple-source generics targeting the same dosage form and pack size
Niche competitor formats (spray vs cream vs powder) that capture OTC shelf attention

What formulations are protected for miconazole and which ones matter commercially?

Answer: For older actives like miconazole, commercial differentiation usually comes from:

vehicle and base (cream vs gel vs spray)
excipient selection for skin tolerability
packaging and dosing convenience
in-vaginal formulation base

Why formulation IP rarely holds pricing power

Even when formulation-related patents exist, topical azoles are often easy to design around, and courts often treat minor excipient changes as insufficient for strong exclusivity. As a result, commercial pricing tends to converge.

What is the pricing model for topical antifungals: list price versus net price?

Answer: In mature OTC and pharmacy channels, list price can remain stable while net price drops through:

pharmacy rebates
wholesaler discounts
promo allowances during retail campaigns

Projection method that business teams should use

Use a two-layer model:

List price trend (minor changes)
Net price trend (bigger changes due to competitive contracting)

Price projection framework for GS MICONAZOLE (practical scenario model)

Answer: Without brand-level NDC price history, the only defensible projections are scenario bands built from category behavior for topical antifungals. Apply erosion rates based on how competitive each geography is and whether GS holds a pack-specific niche.

Scenario assumptions (category-driven)

Mature, highly genericized market (most geographies):
- annual net price erosion: 3%–8%
- occasional promo-driven dips: additional 5%–15% around seasonal peaks
Moderately competitive market (fewer entrants, partial formulary friction):
- annual net price erosion: 1%–3%
- limited promo volatility
Emerging market (GS gains distribution, then faces generic ramp-up):
- years 1–2: net price stable to slightly down (0%–2%)
- years 3–5: erosion accelerates (4%–8%)

Projected price band template (indexed approach)

Index GS net price to year-0 at 100:

Mature scenario:
- Year 1: 92–97
- Year 2: 85–94
- Year 3: 80–90
- Year 5: 70–85
Moderately competitive scenario:
- Year 1: 97–99
- Year 3: 94–97
- Year 5: 90–95
Emerging ramp-and-erosion:
- Year 2: 98–100
- Year 3: 93–98
- Year 5: 80–92

Unit economics sensitivity to pack size

Topical antifungals often vary widely by:

tube size (e.g., 15 g vs 30 g)
spray volume
pessary count for vaginal products

Projections should be executed per SKU pack size to avoid margin misstatement.

What do revenue exposure and demand drivers look like for GS MICONAZOLE?

Answer: Demand is driven by:

recurring dermatology needs
seasonality in skin fungal infections (often higher in warmer/humid months)
retailer promotion intensity and coverage

Major revenue risks

Price compression if GS loses shelf position to lower net-price suppliers
Channel shifts (OTC-to-Rx or vice versa depending on local rules)
Supply interruptions affecting pharmacy continuity and earning losses

Major revenue tailwinds

Contract wins with pharmacy chains
Improved distribution coverage (more store fronts)
Higher-value format adoption (sprays/powders) if supported by demand

How does GS MICONAZOLE compare with leading competitors in the azole OTC class?

Answer: In most markets, competitive superiority is not driven by efficacy differentiation because miconazole and its azole peers show comparable label performance for superficial infections. Pricing position and distribution depth dominate.

Comparison dimensions that determine market outcomes

Net price competitiveness (rebate levels)
Shelf availability (avoid stock-outs)
SKU breadth (strength, pack size, formats)
Promotion calendar (endcaps, seasonal campaigns)

What manufacturing and IP/IP-barriers affect GS MICONAZOLE costs and pricing?

Answer: Cost structure is typically driven by:

raw material procurement of miconazole
base/vehicle manufacturing for creams and gels
filling and packaging line utilization
regulatory quality systems and batch release

Where price can deviate from category erosion

supply chain disruptions of key excipients or filling capacity
changes in packaging cost (labels, cartons, unit-dose components)
compliance upgrades that raise COGS temporarily

In commodity topical azoles, these deviations tend to be temporary.

Where are likely settlement or litigation impacts for miconazole brands?

Answer: For off-patent topical azoles, litigation is usually low relative to specialty branded drugs. When disputes occur, they often target formulation, labeling, or specific product-by-product generic launches. For GS MICONAZOLE, no specific litigation dataset is provided here.

Key Takeaways

GS MICONAZOLE pricing is likely constrained by commodity competition in mature markets; durable premium pricing is limited without enforceable brand-level exclusivity.
Model projections using net price erosion bands consistent with generic OTC antifungal behavior: ~3%–8% annual net erosion in highly competitive markets; ~1%–3% where competition is thinner.
SKU-level granularity is required for accurate forecasting because pack size and format materially change net pricing and margin.
Revenue exposure is demand-plus-promo driven, with seasonality in skin fungal infections and risk centered on loss of shelf position to lower-net-price suppliers.
Largest controllable lever for GS is contracting and distribution coverage that protects net price and minimizes lost units during promotional cycles.

FAQs

1) What is the typical wholesale-to-retail markup structure for OTC topical miconazole?

Wholesale margins and pharmacy rebates determine net price; list price alone usually overstates realized economics.

2) Do miconazole creams and sprays price differently per gram, and why?

Sprays/powders often carry a convenience premium and higher packaging cost, so per-gram pricing can be higher even when base efficacy is similar.

3) How should I forecast GS MICONAZOLE in a pharmacy chain rollout?

Use an indexed SKU model by store count ramp, then apply scenario net price erosion after competitive shelf stabilization.

4) What is the biggest driver of price volatility for topical antifungals?

Promotional contracting and pharmacy network rebates typically drive the biggest short-term dips.

5) Can formulation changes protect pricing for generic miconazole in practice?

Minor vehicle/excipient changes rarely prevent substitution; meaningful pricing protection requires enforceable, product-specific differentiation that limits interchangeability.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
FDA. (n.d.). Drug Approval Reports / Drug Trials Snapshots. US Food and Drug Administration.